Another potential weaker PgP inhibitor and studied in osteosarcoma relapse treatment (NCT02243605) [29], the multi-tyrosine kinase inhibitor cabozantinib, did not revert PgP phenotype when used at a dose that did not inhibit cell proliferation, conversely to what was shown in hepatoblastoma cells [30]. Here, PGP is linked to osteosarcoma.